1. SMPC
  2. ADVERSE EVENT REPORTING
TAGRISSO® (osimertinib)
  • Home
  • Efficacy
    • PFS
    • Subgroups
    • CNS
    • OS
    • DoR/ORR
    • Study design
  • Safety
  • MOA
  • Dosing
  • AURA3
    • PFS
    • CNS
    • Study design
    • Testing
  • Resources
  • AstraZeneca Global Corporate Site
  • Privacy Notice
  • Legal Statement
  • Cookies
  • Site Map
  • Site Map
  • SmPC
  • Adverse Event Reporting
  • Contact Us

This product information is intended for non-US and non-UK Healthcare Professionals only.

TAGRISSO is a registered trademark of the AstraZeneca group of companies.

©2019 AstraZeneca. All rights reserved.

Date of Prep: August 2018 VEEVA ID: Z4-9314 Date of Next Approval: August 2020

For healthcare professionals only.

FIRST-LINE TAGRISSO®

NEW INFORMATION ON
OVERALL SURVIVAL IS HERE

LEARN MORE

Continue to the website

IN THE FLAURA STUDY

Progression-free survival was the primary endpoint.
Overall survival was a prespecified secondary endpoint.

AstraZeneca

TAGRISSO is a registered trademark of the AstraZeneca group of companies.

©2019 AstraZeneca. All rights reserved. Date of preparation: July 2019 Document ID: Z4-17724 Expiry date: July 2020

Tagrisso
AstraZeneca

TAGRISSO is a registered trademark of the AstraZeneca group of companies.

©2019 AstraZeneca. All rights reserved.

Date of preparation: July 2019 Document ID: Z4-17724
Expiry date: July 2020

AstraZeneca